The effect of experimental renal failure on tolfenamic acid disposition in the dog

Biopharmaceutics and Drug Disposition

Volumn 18, Issue 1, 1997, Pages 79-91

  Lefebvre, Hervé P ^a   Laroute, Valérie ^a   Alvinerie, Michel ^b   Schneider, Marc ^b   Vinclair, Patrick ^c   Braun, Jean Pierre ^a   Toutain, Pierre Louis ^a  

^a UNIVERSITÉ DE TOULOUSE   (France)

^b CEMAGREF   (France)

^c Bioanalysis Vetoquinol Magny V   (France)

Author keywords

dogs; non steroidal anti inflammatory drug; pharmacokinetics; renal failure; tolfenamic acid

Indexed keywords

TOLFENAMIC ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG METABOLISM; DRUG PROTEIN BINDING; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; NONHUMAN; PHARMACOKINETICS; STEADY STATE;

ANIMALS; ANTHRANILIC ACIDS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AREA UNDER CURVE; BLOOD PROTEINS; DOGS; FEMALE; INJECTIONS, INTRAVENOUS; KIDNEY FAILURE, ACUTE; METABOLIC CLEARANCE RATE; NEPHRECTOMY; PROTEIN BINDING;

EID: 0031034275     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-081X(199701)18:1<79::AID-BDD34>3.0.CO;2-F     Document Type: Article

References (21)

1. S. O. Pedersen, Biopharmaceutical aspects of tolfenamic acid. Pharmacol. Toxicol., 75 (suppl. II), 22-32 (1994).
2. P. J. Pentikaïnen, O. Tokola, E. Alhava and A. Penttilä, Pharmacokinetics of tolfenamic acid: disposition in bile, blood and urine after intravenous administration to man. Eur. J. Clin Pharmacol., 27, 349-354 (1984).
3. C. Y. Chen, C. V. F. Pang and C. S. Chen, Assessment of ibuprofen-associated nephrotoxicity in renal dysfunction. J. Pharmacol. Exp. Ther., 270, 1307-1312 (1994).
4. C. Y. Chen and C. S. Chen, Stereoselective disposition of ibuprofen in patients with renal dysfunction. J. Pharmacol. Exp. Ther., 268, 590-594 (1994).
5. R. Zini, P. Riant, J. Barré and J. P. Tillement, Disease-induced variations in plasma protein levels, implications for drug dosage regimens (part I). Clin. Pharmacokinet., 19, 147-159 (1990).
6. A. P. Van Peer and F. M. Belpaire, Hepatic oxidative drug metabolism in rats with experimental renal failure. Arch. Int. Pharmacodyn. Thér., 228, 180-183 (1977).
7. J. Hendel, The overall safety of tolfenamic acid. Pharmacol. Toxicol., 75, suppl. II, 53-55 (1994).
8. J. V. White, D. R. Finco, W. A. Crowell, S. A. Brown and D. A. Hirakawa, Effect of dietary protein on functional, morphologic and histologic change of the kidney during compensatory renal growth in dogs. Am. J. Vet. Res., 52, 1357-1365 (1991).
9. J. F. Roe, J. H. Epstein and N. P. Goldstein, A photometric method for the determination of inulin in plasma and urine. J. Biol. Chem., 178, 839-845 (178).
10. J. Hamburger, A. Ryckewaert, M. Duizend and N. Argant, Dosage du PAH. In Choix de Techniques de Biochimie Clinique, 2nd edn, G. Devaux et al. (Eds), Gauthiers-Villars, Paris, 1970, pp. 335-336.
11. P. J. Pentikaïnen, P. J. Neuvonen and C. Backman, Human pharmacokinetics of tolfenamic acid, a new anti-inflammatory agent. Eur. J. Clin. Pharmacol., 19, 359-365 (1981).
12. R. S. Cotran, R. H. Rubin and N. E. Tolkoff-Rubin, Tubulointerstitial diseases. In The Kidney, 3rd edn, B. M. Brenner and F. C. Rector (Eds), Saunders, Philadelphia, PA, 1986, pp. 1143-1173.
13. D. R. Finco, Kidney function. In Clinical Biochemistry of Domestic Animals, 4th edn, J. J. Kaneko (Ed.), Academic, San Diego, CA, 1989, pp. 496-542.
14. N. E. Duffee, R. F. Bevill, G. D. Koritz and D. J. Schaeffer, An experimental model for pharmacokinetic analysis in renal failure. J. Pharmacokinet. Biopharm., 18, 71-86 (1990).
15. M. Antilla, M. Haataja and A. Kasanen, Pharmacokinetics of naproxen in subjects with normal and impaired renal function. Eur. J. Clin. Pharmacol., 18, 263-268 (1980).
16. N. Priymenko, J. P. Ferré, A. Rascol, G. Costes and P. L. Toutain, Migrating motor complex of the intestine and absorption of a biliary excreted drug in the dog. J. Pharmacol. Exp. Ther., 267, 1161-1167 (1993).
17. J. Y. Kang, The gastrointestinal tract in uremia. Dig. Dis. Sci., 38, 257-268 (1993).
18. M. M. Reidenberg and D. E. Drayer, Alteration of drug-protein binding in renal disease. Clin. Pharmacokinet., 9 (suppl. 1), 18-26 (1984).
19. A. C. Rudy, P. M. Knight, D. C. Brater and S. D. Hall, Enantioselective disposition of ibuprofen in elderly persons with and without renal impairment. J. Pharmacol. Exp. Ther., 273, 88-93 (1995).
20. A. C. Rudy, N. L. Figueroa, S. D. Hall and D. C. Brater, The pharmacokinetics of piroxicam in elderly persons with and without renal impairment. Brit. J. Clin. Pharmacol., 37, 1-5 (1994).
21. A. Kuninaka, K. Sungai, K. Saito, N. Mori, R. Kimura and T. Murata, Study on the metabolism of a new anti-inflammatory drug N-(2-methyl-3-chlorophenyl)-anthranilic acid (GEA 6414). Urinary metabolites in human beings, dogs and rabbits. Yakugaku Zasshi, 101, 232-238 (1981).